Core Viewpoint - Eddiecon Holdings (09860) announced the acquisition of 100% of the issued shares of Crown Bioscience International for a total purchase price of $204 million, which aligns with the company's strategy to expand its product portfolio and is expected to bring long-term strategic benefits [1][2]. Group 1: Acquisition Details - The buyer, Miramar Lifesciences Limited, a wholly-owned subsidiary of Eddiecon, entered into a share purchase agreement with the seller, JSR Life Sciences, LLC, regarding the acquisition of the target company [1]. - Upon completion of the transaction, Crown Bioscience International will become a wholly-owned subsidiary of Miramar Lifesciences Limited [1]. - The target company is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. Group 2: Company Operations - Eddiecon primarily provides Integrated Clinical Laboratory (ICL) services, along with medical testing, clinical trials, research services, health management, and pathology consultation services [1]. - The company focuses on research and development in core disease areas such as infectious diseases, women's health, solid tumors, perinatal and pediatric care, and hematology, covering multiple disciplines including internal medicine, pediatrics, obstetrics and gynecology, oncology, and neurology [1].

Core Viewpoint - The acquisition of Crown Bioscience International by Miramar Lifesciences Limited for a total purchase price of $204 million is expected to enhance the product portfolio of the company and provide long-term strategic benefits [1][2]. Company Overview - The target company, Crown Bioscience International, is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. - The company collaborates with biotechnology and pharmaceutical firms to accelerate drug development through integrated preclinical, translational, and clinical biomarker services [1]. Strategic Rationale - The board believes that the acquisition aligns with the group's development strategy to expand its product offerings [2]. - The acquisition is anticipated to bring long-term and strategic benefits to the company [2].

欢迎扫描下方二维码关注： 》》非营利性科研机构是什么? > 非营利性科研机构要以 推动科技进步为宗旨,不以营 利为目的,主要从事应用基础 研究或向社会提供公共服务。 > 非营利性科研机构的认 定标准,由科技部会同财政 部、中编办、国家税务总局另 行制定。 > 非营利性科研机构需要 书面向科技行政主管部门申明 其性质,按规定进行设置审批 和登记注册,并由接受其登记 注册的科技行政部门核定,在 执业登记中注明"非营利性科 研机构"。 → 非营利性科研机构的认定标准,由科技部会同 财政部、中编办、国家税务总局另行制定。非营利性 科研机构需要书面向科技行政主管部门申明其性 质,按规定进行设置审批和登记注册,并由接受其 登记注册的科技行政部门核定,在执业登记中注明 "非营利性科研机构"。 政策依据 /《财政部 国家税务总局关于非营利性科研 机构税收政策的通知》财税〔2001〕5号 >优惠政策 > 非营利性科研机构自用的房产、土地,免征房 产税、城镇土地使用税。 》享受主体 → 非营利性科研机构 》申请条件 》申报时点 日 12 * = = > 根据房产税、城镇土地使用税纳税义务发生时 间,在规定的纳税期限内申报。 来源 ...

Group 1 - The 2025 China International Service Trade Fair will be held in Beijing from September 10 to 14, showcasing the development of China's service industry and trade [1] - The Chinese government emphasizes the importance of accelerating the innovation and development of service trade in response to external environmental changes and industrial restructuring [1][3] - The Ministry of Commerce plans to introduce a series of policy measures to support service exports, focusing on fiscal, financial, and facilitation aspects [1][5] Group 2 - In the first half of the year, China's service trade import and export total reached a record high of 3.9 trillion yuan, with a year-on-year growth of 8% [2] - Service exports amounted to 1.7 trillion yuan, growing by 15%, with transportation and travel services being the largest and fastest-growing sectors, respectively [2] - Knowledge-intensive service exports also showed potential, with a total of 865.04 billion yuan, growing by 7.8% [2] Group 3 - The government aims to promote high-quality service imports and enhance the quality of the service industry through a more open service trade system [3] - There is a focus on expanding emerging service exports in areas such as artificial intelligence, biomedicine, and digital economy [3] - The Ministry of Commerce is set to release new policies to boost service exports and enhance domestic service consumption [5][6]

Core Viewpoint - The Chinese government is accelerating the implementation of policies to support service trade, indicating a positive growth trend in this sector [1][2]. Group 1: Policy Initiatives - The State Council's recent study emphasizes the need to enhance the international competitiveness of service exports, focusing on areas such as research, consulting, e-commerce, and digital service trade [2]. - The Ministry of Commerce plans to introduce a series of measures to promote service exports, including optimizing zero tax rate declaration procedures and increasing export credit insurance support [2][5]. - The government aims to leverage the effects of visa-free policies to attract more foreign tourists, thereby boosting travel service exports [2][3]. Group 2: Service Trade Growth - The global service export is projected to grow by 4% by 2025, with major economies showing robust growth in service trade during the first half of the year [1]. - In the first half of the year, transportation service exports reached 418.5 billion yuan, growing by 23.9%, while travel service exports surged to 174.87 billion yuan, marking a 68.7% increase [2][5]. Group 3: Digital Service Trade - The development of digital service trade is prioritized, with a focus on cross-border e-commerce and the digital transformation of trade processes [3]. - The Ministry of Commerce is set to promote and regulate cross-border data flow, which is crucial for many multinational companies [3]. Group 4: Negative List Management - The reduction of the negative list for cross-border service trade is a key strategy for expanding service imports [3][4]. - The government is actively monitoring the implementation of the negative list and addressing any challenges that arise [4]. Group 5: Future Outlook - The next phase is expected to see increased support from fiscal, tax, financial, and regulatory measures for service trade, particularly service exports [5]. - Overall, service trade is anticipated to maintain growth throughout the year, with an ongoing optimization of trade structure [5].

Group 1 - The core point of the article highlights the stock performance of Kingmed Diagnostics, which closed at 30.73 yuan on August 5, showing a slight decline of 0.09 yuan or 0.29% from the previous trading day [1] - On August 5, the stock opened at 30.85 yuan, reached a high of 31.38 yuan, and a low of 30.40 yuan, with an overall trading range of 3.18% and a trading volume of 84,190 hands, amounting to 260 million yuan [1] - Kingmed Diagnostics is a leading third-party medical testing institution in China, with its main business covering medical testing, pathological diagnosis, and research services, supported by a nationwide service network [1] Group 2 - At 13:01 on August 5, Kingmed Diagnostics experienced a rapid rebound, with a price increase of over 2% within 5 minutes, rising from 30.96 yuan to 31.21 yuan, with a transaction volume of 165 million yuan during that period [1] - Despite a net outflow of 7.02 million yuan in main funds by the end of the trading day, there was a cumulative net inflow of 53.83 million yuan over the past five trading days [1]

Industry Outlook - The third-party medical diagnostic service industry is rapidly developing, with ICL expected to benefit from cost and technology advantages [3] - ICL's chain operators have a broader laboratory network compared to hospital laboratories, allowing for lower costs and more testing projects [3] - New technologies such as AI pathology diagnosis and automated laboratory systems are anticipated to reshape the industry [3] Financial Performance - In 2024, the company achieved a revenue of CNY 174,218.10 million, a year-on-year increase of 4.05% [9] - The medical diagnostic service revenue was CNY 79,716.65 million, growing by 23.26%, contributing significantly to overall revenue growth [9] - The company reported a net profit of -CNY 10,943.62 million, a reduction in losses by 22.71% compared to the previous year [9] Operational Strategies - The company is focusing on digital transformation and information technology to enhance operational efficiency and service quality [5] - A dual-driven business model is being implemented to achieve full-process digitalization from sample receipt to laboratory testing [5] - The company aims to diversify its supplier base to mitigate risks associated with reliance on major suppliers, which account for 65.28% of procurement [6] Future Growth Drivers - The main growth drivers include stable revenue from core business operations and effective management of operational costs [5] - The company plans to enhance its capabilities in CRO (Contract Research Organization) and scientific services, which are showing growth potential [10] - Continued investment in AI medical applications is expected to create new revenue streams, although profitability in this area has not yet been achieved [11] Environmental Initiatives - The company is committed to energy management and has set specific goals for reducing emissions related to laboratory energy consumption and hazardous material transport [12] - A cold chain logistics system has been established to ensure safe and efficient transportation of clinical samples and medical devices [10] Challenges and Responses - The industry faces pressure from healthcare cost control measures, prompting the company to enhance its business model and expand its marketing network [12] - The company is adapting to seasonal revenue fluctuations and aims to stabilize profitability through improved operational efficiency [8]